Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of Segment Profit or Loss and Significant Segment Expenses

Additional information about segment profit or loss and significant segment expenses is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Direct R&D program expense
BHV-4157 (Troriluzole)	$	14,245	$	17,076	$	28,033	$	34,163
BHV-2000 (Taldefgrobep Alfa)	8,045		17,748		14,229		28,876
BHV-7000 & BHV-7010 (Kv7)	31,172		27,400		62,744		52,204
BHV-2100 (TRPM3 Antagonist)	6,845		4,272		23,594		8,892
BHV-8000 (TYK2/JAK1)	21,216		2,675		25,589		6,925
BHV-1300 (IgG Degrader)	11,732		7,358		20,352		16,583
BHV-1310 (IgG Degrader)	3,612		3,938		4,686		7,199
BHV-1400 (IgA Degrader)	6,737		7,612		11,597		11,704
BHV-1600 (β1-AR AAB Degrader)	1,806		3,009		4,809		3,825
BHV-1510 (TROP-2)	5,384		3,043		9,873		22,628
BHV-1530 (FGFR3)	15,393		—		18,569		—
Other R&D program expense	1,104		1,272		1,615		1,030
Preclinical research programs R&D Expense	16,398		15,081		41,933		26,944
R&D personnel expense (excluding share-based compensation)(1)	20,490		17,889		41,627		37,202
R&D Share-based compensation expense	13,110		7,071		48,344		28,362
R&D Knopp amendment expense	—		171,850		—		171,850
G&A personnel expense (excluding share-based compensation)(1)	6,004		6,122		12,478		12,510
G&A Share-based compensation expense	7,702		5,161		25,530		18,747
Other segment items (2)	20,706		15,195		37,660		27,368
Non-operating income	(13,815)		(14,178)		(14,308)		(18,483)
Provision for income taxes	261		177		870		746
Segment net loss	198,147		319,771		419,824		499,275

Reconciliation of profit or loss
Adjustments and reconciling items	—		—		—		—
Consolidated net loss	$	198,147	$	319,771	$	419,824	$	499,275

(1) Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.

(2) Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.